Actemra claims advantage over Humira in rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
Roche is claiming victory for Actemra (tocilizumab) over Abbott's rival rheumatoid arthritis drug Humira (adalimumab) in the first head-to-head study between the two products in a monotherapy setting.